Fosun Pharmaceutical

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (referred to as "Fosun Pharma," stock code: 600196.SH, 02196.HK) was established in 1994 and is a leading innovative and international healthcare industry group in China. The company strategically deploys its businesses across the pharmaceutical and healthcare industry chain, directly operating businesses including pharmaceuticals, medical devices and diagnostics, and healthcare services. It also extends to the pharmaceutical commercial sector through its participation in Sinopharm Holding.With pharmaceuticals as its core business, Fosun Pharma adheres to innovative R&D. Through self-research, cooperative development, licensing, and deep incubation, it focuses on key disease areas such as oncology and immunomodulation, the "four highs" (hypertension, hyperlipidemia, hyperglycemia, hyperuricemia) and their complications, and the central nervous system. The company has built and formed platforms for small-molecule innovative drugs, antibody drugs, and cell therapy technologies while actively exploring frontier technology fields such as targeted protein degradation, RNA, oncolytic viruses, and gene therapy to enhance its innovation capabilities.Looking ahead, under the guidance of its "4IN" strategy (Innovation, Internationalization, Integration, Intelligentization), Fosun Pharma will adhere to the development model of "innovative transformation, integrated operation, and steady growth" along with the concept of sustainable development. It aims to become a first-class enterprise in the global mainstream healthcare market.